SynthesisScientific reports2025
Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups remains poorly understood. This study aimed to evaluate age-related survival outcomes in aRCC patients receiving ICI using integrated cohorts. Using data from the Surveillance, Epidemiology, and End Results (SEER) program (2004-2021), we identified patients with aRCC across the pre-ICI and ICI eras and stratified them into younger (<65 years) and older (≥65 years) groups. Survival analyses, including Kaplan-Meier curves and multivariate Cox regression models, were performed to assess overall survival (OS). Key prognostic factors, such as tumor grade, surgical intervention, and metastatic status, were analyzed using nomograms and receiver operating characteristic (ROC) curves for predictive accuracy. A systematic search of PubMed, Web of Science, and Scopus also identified ten randomized controlled trials (RCTs) that met the meta-analysis criteria. Odds ratios (ORs) were calculated to evaluate age-stratified survival outcomes. Finally, laboratory-based immunohistochemistry (IHC) analysis of TNFSF15, an immune-related biomarker, was performed to explore molecular age-related differences in a hospital cohort. The SEER cohort included 21,904 patients (11,814 in the pre-ICI era and 10,090 in the ICI era). Age showed no significant impact on survival in the pre-ICI era (HR 1.050; 95% CI 0.97-1.32; p=0.203), while younger patients demonstrated superior outcomes in the ICI era (median OS, 16 vs. 13 months; HR, 1.37; 95% CI 1.24-1.51; p = 0.0001). Meta-analysis of 8,434 patients (4,207 ICI group, 4,227 control group) revealed significantly improved survival in younger patients receiving ICI (pooled OR 0.76; 95% CI 0.64-0.89; p<0.0001), whereas the non-ICI cohort showed no significant age-dependent effects (pooled OR 0.93; 95% CI 0.79-1.09; p = 0.37).When comparing ICI versus control treatments, younger patients derived greater benefit (HR 0.69 [0.62, 0.77]) than older patients (HR 0.84 [0.74, 0.96]) p<0.0001). TNFSF15 expression demonstrated a significant negative correlation with age (Spearman correlation = - 0.6, p = 0.0001), with significantly higher expression in patients aged <65 years to those ≥65 years (p=0.0001). This comprehensive analysis demonstrates the superior efficacy of ICI in younger aRCC patients across multiple cohorts, supporting the development of age-stratified therapeutic approaches. Age-dependent expression of TNFSF15 suggests potential molecular mechanisms underlying differential treatment responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.